Welcome to our dedicated page for Insulet SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Insulet Corporation (NASDAQ: PODD) SEC filings, offering a structured view of the company’s regulatory disclosures as a NASDAQ-listed medical device manufacturer. Insulet develops the Omnipod tubeless insulin pump platform and the Omnipod 5 Automated Insulin Delivery System, and its filings help investors understand how this business is governed, financed, and overseen.
Through Forms 10-K and 10-Q, Insulet reports audited and interim financial statements, risk factors, and management’s discussion of its Omnipod product platform, manufacturing operations, and growth strategy in automated insulin delivery and related drug delivery applications. Current reports on Form 8-K disclose material events such as quarterly financial results, amendments to incentive and severance plans, executive leadership transitions, and appointments to the board of directors and committees.
Investors can also review proxy statements for details on executive and director compensation, governance structures, and shareholder matters, as well as any registration statements related to securities offerings. For monitoring insider activity, Forms 3, 4, and 5 report beneficial ownership and changes in holdings by Insulet’s officers, directors, and other insiders, which some investors use to gauge management’s alignment with shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify important changes in financial performance, risk disclosures, compensation arrangements, or governance. Real-time updates from the SEC’s EDGAR system ensure that new Insulet filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider transaction reports, appear promptly, while AI-generated explanations make complex regulatory language more accessible to a broad range of investors and researchers.
Insulet Corporation announced a voluntary medical device correction for specific lots of its Omnipod® 5 Pods in the U.S. after identifying a manufacturing issue that can cause small tears in internal tubing and under-delivery of insulin.
The company has received 18 reports of serious adverse events tied to high blood glucose and diabetic ketoacidosis, but no deaths, and has notified the FDA. The affected lots represent about 1.5% of annual Omnipod 5 pod production, and Insulet does not expect shipment or new-patient-start disruptions. Customers can check lot numbers online and obtain free replacement Pods.
Insulet currently expects to incur up to $40 million of related costs in 2026, which will be excluded from adjusted results, and it is not changing previously issued 2026 guidance.
Insulet Corporation reported entering into a severance agreement and release with former Chief Financial Officer Ana M. Chadwick. The agreement implements severance and other post-termination benefits that were already disclosed under prior arrangements and the company’s Amended and Restated Executive Severance Plan.
The filing explains that the Severance Agreement does not add or change any material compensation or benefits terms. It includes standard provisions such as a release of legal claims, mutual non-disparagement, and requirements that Ms. Chadwick comply with existing executive severance and confidentiality, non-solicit, non-compete, and intellectual property assignment agreements.
INSULET CORP senior vice president Prem Singh reported routine share dispositions related to tax withholding on vested equity. On February 27, 2026, a total of 269 shares of common stock were withheld at $246.61 per share to cover tax obligations from restricted stock units vesting. These transactions are coded as tax-withholding dispositions, not open-market sales, and Singh continued to hold several thousand shares directly afterward.
INSULET CORP senior vice president Laetitia Cousin reported small share disposals tied to tax withholding, not open-market selling. On the vesting of restricted stock units, 200 and 53 shares of common stock were withheld at a price of $246.61 per share to cover associated tax obligations. After these transactions, she directly held 5,674 shares of Insulet common stock.
INSULET CORP executive reports tax-related share withholdings
Insulet Corp Group VP, CAO and Controller Lauren Budden reported two Form 4 transactions on common stock dated February 27, 2026. The transactions were coded "F," meaning shares were withheld to satisfy tax obligations upon vesting of restricted stock units, rather than open-market sales.
Budden had 119 shares and 99 shares withheld at a reference price of $246.61 per share to cover associated taxes. Following these non-market dispositions, she directly holds 8,526 shares of Insulet common stock.
Insulet Corp SVP and General Counsel John W. Kapples reported routine share withholding to cover taxes on vested stock awards. On February 27, 2026, 411 and 194 shares of Insulet common stock were disposed of at $246.61 per share through tax-withholding transactions.
According to the filing, these dispositions were for tax obligations tied to restricted stock units vesting, rather than open-market sales. After these transactions, Kapples directly held 27,514 shares of Insulet common stock.
INSULET CORP EVP and COO Eric Benjamin reported tax-related share dispositions, not open-market sales. On February 27, 2026, he surrendered 644 and 268 shares of common stock at $246.61 per share to cover tax obligations upon vesting of restricted stock units, and continued to hold directly owned shares afterward.
INSULET CORP senior executive Prem Singh reported routine equity compensation activity. He received a grant of 2,140 shares of common stock as a restricted stock unit award that vests over three years and 5,570 non-qualified stock options that vest over four years. On a separate date, 138 shares of common stock were withheld to satisfy tax obligations upon RSU vesting, a non-market transaction, leaving him with 7,160 directly owned shares.
INSULET CORP senior vice president Laetitia Cousin reported equity compensation and related tax withholding transactions. She received an annual grant of 1,044 shares of common stock as restricted stock units that vest in three substantially equal installments on the first, second and third anniversaries of the grant date.
She also received an annual non-qualified stock option award for 2,718 shares that becomes exercisable in four substantially equal installments on each of the first four anniversaries of the grant date. In a separate transaction, 111 shares of common stock were withheld at a price of $248.12 per share to cover tax obligations upon RSU vesting.
Insulet Corp Group VP, CAO and Controller Lauren Budden reported routine equity compensation transactions. She received a grant of 611 shares of common stock and an option for 1,591 shares, both at a grant price of $0.00 per share, reflecting stock-based awards rather than open‑market activity.
To cover taxes on vested restricted stock units, 55 shares of common stock were withheld at a price of $248.12 per share, characterized as a tax-withholding disposition. Following these transactions, she directly owned 8,744 common shares and held an option for 1,591 shares, with vesting and exercisability occurring in installments over several years.